ArticleDiscover oncology2026
Omics analysis reveals the prognostic value of IPCDS models and potential targets for immunotherapy.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer remains a major threat to women’s health worldwide. The study aims to investigate the role of immune-related programmed cell death (IPCD) pathways and related genes in breast cancer progression and prognosis.
methodsWe analyzed multi-omics datasets from TCGA, ICGC, and multiple GEO cohorts to screen for IPCD-related differentially expressed genes (DEGs) and established an IPCD-based signature (IPCDS) model for prognosis via 101 machine learning algorithm combinations. Functional enrichment analysis, survival analysis, principal component analysis (PCA), and immune correlation analysis were conducted by packages in R software.
resultsThe screened IPCD-related DEGs were primarily enriched in the MAPK and PI3K-AKT signaling pathways, as well as focal adhesion. Across different cohorts, patients in the high-IPCDS groups showed the worse overall survival than those in the low-IPCDS groups, indicating the robust prognostic value. The IPCDS model demonstrated a higher C-index than other published models. To predict the response to immunotherapy, application of the TIDE algorithm to TCGA data revealed a significant significant association between IPCDS and immunotherapy response; the low-IPCDS group had a lower TIDE score, while non-responders had a higher IPCDS score. Furthermore, the IPCDS score was negatively correlated with SIAH2 expression. High expression of SIAH2 predicted better survival and was inversely correlated with immune scores, suggesting its potential role as a protective biomarker [hazard ratios (HR) = 0.64]. A significant negative correlation was also observed between SIAH2 and CD8A expression (p = 0.0011).
conclusionWe established and validated a robust IPCDS model that effectively prognosticates breast cancer patients and predicts immunotherapy response. The model addresses the gap in integrating immune and programmed cell death pathways into a unified prognostic framework, outperforms existing models, and nominates SIAH2 as a potential key regulator. The elevated expression of SIAH2 is associated with a lower IPCD score, which in turn correlates with improved overall survival and reduced CD8 + T cell infiltration, highlighting its translational potential in guiding immune-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.